Non-Small Cell Lung CancerPhase 1NCT00907179
Pemetrexed and LBH589 in Patients With Advanced Non-Small Cell Lung Cancer
A Phase 1 study testing LBH 589 and Pemetrexed in people with Non-Small Cell Lung Cancer, run by University of Pittsburgh at 1 site in United States.
Trial summary
LBH589 is a drug that may slow down the growth of cancer cells or kill cancer cells by blocking certain enzymes. LBH589 has shown effects against cancer in laboratory studies and in studies using animals; however, it is not known if this medicine will show the same activity in humans. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Non-Small Cell Lung Cancer
- What is being tested?
- LBH 589 and Pemetrexed
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 12 participants
- Where
- 1 siteUnited States
- Study dates
- Jul 2009to Jul 2015
- Phase
- Phase 1
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Phase I only: any number of prior regimens is allowed and all thoracic malignancies, except squamous cell carcinoma of the lung.
- Phase II only: Patients with recurrent or progressive advanced stage non-squamous cell NSCLC (no small cell lung cancer/SCLC component) who have received 1 prior chemotherapy regimen for advanced NSCLC. Chemotherapy as part of initially potentially curative therapy that was completed <1 year counts as 1 prior regimen. Prior erlotinib or one other biologic regimen is also allowed.
- Measurable disease (RECIST) (for phase II part only)
- Patients may not have received prior pemetrexed or histone deacetylase inhibitor (HDACi) therapy, including valproic acid, for the treatment of any medical condition.
- ECOG (Eastern Cooperative Oncology Group) Performance Status of ≤ 2
- Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
Show all 29Show fewer
- Patients must meet the following laboratory criteria:
- Hematology:
- Absolute neutrophil count (ANC) ≥ 1500/mm³
- Platelets ≥ 100,000/mm³
- Hemoglobin ≥ 9 g/dL
- Biochemistry:
- Total Bilirubin within normal institutional limits.
- Aspartate aminotransferase/glutamic oxaloacetic transaminase (AST/SGOT) and alanine aminotransferase/glutamic pyruvic transaminase (ALT/SGPT) ≤ 2.5 x upper limit of normal (ULN)
- Creatinine clearance 45 ml/min or higher calculated using the Cockcroft-Gault formula
- Total serum calcium (corrected for serum albumin) or ionized calcium within normal limits (WNL)
- Serum potassium ≥ WNL
- Serum sodium ≥ WNL
- Serum albumin ≥ WNL
- Patients with any elevated Alkaline Phosphatase due to bone metastasis can be enrolled
- Baseline multiple uptake gated acquisition scan (MUGA) or ECHO must demonstrate left ventricular ejection fraction (LVEF) ≥ the lower limit of the institutional normal.
- Thytoid stimulating hormone (TSH) and free T4 within normal limits (patients may be on thyroid hormone replacement)
- Blood pressure of <140/90.
- Patients must have fully recovered from the effects of any prior surgery, chemotherapy or radiation therapy. A minimum time period of 3 weeks should elapse between the completion of extensive radiation therapy for recurrent/metastatic disease and enrollment in the study. A minimum of 4 weeks should elapse between the completion of chemotherapy or any experimental therapy and enrollment in the study. At least 2 weeks should have elapsed from prior erlotinib or other biologic therapy.
- If patient has history of brain metastases, brain lesions should have been treated with surgery and/or radiation and be stable on repeat imaging.
- No history of prior malignancy, with the exception of curatively treated squamous cell or basal carcinoma of the skin or in situ cervical cancer, unless there is a 3- year disease-free interval.
- Patients should temporary stop certain Nonsteroidal Anti-inflammatory Drug (NSAIDS) starting 5 days prior to protocol therapy, as described in 6.5.1.
- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days of the first administration of study treatment and must be willing to use two methods of contraception one of them being a barrier method or abstain from sexual activity during the study and for 3 months after last study drug administration. Sexually active males and their female partners must agree to use two methods of accepted and effective method of contraception (hormonal or barrier methods, abstinence) prior to study entry and for the duration of the study.
- All patients must have given signed, informed consent prior to registration on study.
Who cannot join
- Prior HDAC, deacetylase (DAC), HSP90 inhibitors or valproic acid for the treatment of cancer
- Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first LBH589 treatment
- Impaired cardiac function including any one of the following:
- Screening ECG with a QTc > 450 msec confirmed by central laboratory prior to enrollment to the study
- Patients with congenital long QT syndrome
- History of sustained ventricular tachycardia
Show all 24Show fewer
- Any history of ventricular fibrillation or torsades de pointes
- Bradycardia defined as heart rate < 50 beats per minute. Patients with a pacemaker and heart rate ≥ 50 beats per minute are eligible.
- Patients with a myocardial infarction or unstable angina within 6 months of study entry
- Congestive heart failure (NY Heart Association class III or IV)
- Right bundle branch block and left anterior hemiblock (bifascicular block)
- Uncontrolled hypertension. Patients with history of hypertension must be well-controlled (≤150/100) on a stable regimen of anti-hypertensive therapy.
- Concomitant use of drugs with a risk of causing torsades de pointes (See Appendix 1.-1)
- Concomitant use of Cytochrome (CYP3A4) inhibitors (See Appendix 1-2) is not allowed. The use of cytochrome (CYP2D6) substrates (Appendix 1, table 0-3) should be done with caution. If drugs that are CYP2D6 substrates arte to be continued, patients should be carefully monitored and may require dose titration or dose reduction of the CYP2D6 substrate.
- Patients with unresolved diarrhea > CTCAE (NCI common terminology criteria for adverse events ) grade 1
- Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral LBH589
- Other concurrent severe and/or uncontrolled medical conditions
- Patients who have received chemotherapy, any investigational drug or undergone major surgery < 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
- Concomitant use of any anti-cancer therapy or radiation therapy.
- Women who are pregnant or breast feeding or women of childbearing potential (WOCBP) not willing to use a double barrier method of contraception during the study and 3 months after the end of treatment. One of these methods of contraception must be a barrier method. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months). Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days of the first administration of oral LBH589.
- Male patients whose sexual partners are WOCBP not using a double method of contraception during the study and 3 months after the end of treatment. One of these methods must be a condom
- Patients with known positivity for human immunodeficiency virus (HIV) ) or hepatitis C; baseline testing for HIV and hepatitis C is not required
- Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent
- Patients with squamous cell carcinomas will be excluded
Trial locations and contacts
1 site in 1 country.
United States1 site
Hillman Cancer Center
Pittsburgh, Pennsylvania, 15232
About this study
Official title: Pemetrexed and LBH589 in Previously-Treated Patients With Advanced Non-Small Cell Lung Cancer
LBH589 is a drug that may slow down the growth of cancer cells or kill cancer cells by blocking certain enzymes. LBH589 has shown effects against cancer in laboratory studies and in studies using animals; however, it is not known if this medicine will show the same activity in humans. As of May 2006, approximately 100 patients have received treatment with either an intravenous or capsule form of LBH589. Only the capsule form of LBH589 will be used in this study. In addition, information from other research studies and laboratory studies suggests that this study drug may help to treat lung cancer.
The main goal during the Phase I portion of this research study is to find out the highest and safest dose of LBH589 that can be given in combination with pemetrexed in subjects with lung cancer without causing severe side effects. The main goal of the Phase II portion of this study is to find how the patient's lung cancer responds to the LBH589 in combination with pemetrexed.
This study will also investigate how the patient's body processes the combination of LBH589 and pemetrexed. To determine this, the investigators will measure the amount of study drug in the patient's blood. This will be done with a series of blood tests, called pharmacokinetic (PK) tests. Other purposes of this study will be to determine the side effects of LBH589 in combination with pemetrexed and whether or not this combination is effective in treating your type of cancer.
Read the detailed description
Objectives
- To determine the maximum tolerated dose of LBH589 given on a three times weekly schedule when combined with pemetrexed for the treatment of patients with advanced thoracic malignancies, except squamous cell carcinoma of the lung (phase I part).
- To determine the overall response rate and non-progression rate (clinical benefit rate) and progression-free survival of the combination of LBH589 and pemetrexed in patients with previously-treated advanced NSCLC (phase II part).
- To determine the pharmacodynamic effects of LBH589 and pemetrexed on levels of histone deacetylase (HDAC) 1 and 6 in peripheral blood mononuclear cells, as well as on levels of vascular endothelial growth factor (VEGF) levels in the blood.
- To identify biomarkers in baseline, archival tumor tissue that may correlate with antitumor efficacy.
Subject population Phase I: We will enroll patients treated with any number of prior regimen and all thoracic malignancies, except squamous cell carcinoma of the lung.
Phase II: We will enroll patients with recurrent or progressive NSCLC who have received 1 prior chemotherapy regimen (1 additional regimen in the setting of initial curative treatment is allowed if completed >1 year earlier).
Treatment plan
- Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given.
- LBH589 three-times-a-week (doses will be at least 2 days apart, e.g. Monday, Wednesday, Friday), until disease progression or intolerable toxicities LBH589 will start the week prior to the first pemetrexed cycle and pharmacodynamic (PD) studies will be performed (week -1)
Study design and sample size:
This is a phase I/II study. Phase I: 9-18 patients (estimated); Phase II: 17-41 patients (estimated).
- Conditions
- Non-Small Cell Lung Cancer
- Being tested
- LBH 589, Pemetrexed
- Medical subject headings
- Carcinoma, Non-Small-Cell Lung
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LBH 589Drug
Also called Panobinstat
LBH589 three-times-a-week (doses will be at least 2 days apart, e.g. Monday, Wednesday, Friday), until disease progression or intolerable toxicities LBH589 will start the week prior to the first pemetrexed cycle and PD studies will be performed (week -1).
Dose level: 1 LBH589: 10 mg Pemetrexed: 500 mg/m2
Dose level: 2 LBH589: 15 mg Pemetrexed: 500 mg/m2
Dose level: 3 LBH589: 20 mg Pemetrexed: 500 mg/m2
Dose level: 4 LBH589: 30 mg Pemetrexed: 500 mg/m2
PemetrexedDrug
Also called Alimta
Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given.
| Study group | Role | What they receive |
|---|---|---|
| Dose escalation | Experimental | Phase I: Determine the highest and safest dosage of LBH589 (15 mg, 20 mg, and 30 mg). If the 15 mg dosage causes too many side effects, a back-up dosage of 10 mg will be used instead of the 15 mg.
Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given Receives: Drug: LBH 589; Drug: Pemetrexed |
What is being measured
The primary outcome is the main question the study is designed to answer.
To determine the maximum tolerated dose of LBH589 given on a three times weekly schedule when combined with pemetrexed for the treatment of patients with advanced thoracic malignancies, except squamous cell carcinoma of the lung (phase I part)
Measured: 6 months
Secondary outcomes (3)
Determine the overall response rate and non-progression rate (clinical benefit rate) and progression-free survival of the combination of LBH589 and pemetrexed in patients with previously-treated advanced NSCLC (phase II part).
Measured: 1 year
Determine the pharmacodynamic effects of LBH589 and pemetrexed on levels of HDAC 1 and 6 in peripheral blood mononuclear cells, as well as on levels of VEGF levels in the blood.
Measured: 1 year
Identify biomarkers in baseline, archival tumor tissue that may correlate with antitumor efficacy.
Measured: 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 May 2009 (estimated)
- Study startJul 2009
- Primary completionJul 2015
- Study completionJul 2015
Why it stopped: Widespread use firstline Pemetrexed; slow recruitment; funding withdrawn..
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Non-Small Cell Lung CancerStudies of the same condition, open and under way.
- More trials run by University of PittsburghThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 12 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of Pittsburgh
- Sponsor type
- University, hospital or other
- Collaborators
- Novartis Pharmaceuticals
- Responsible party
- Sponsor
- Investigators
- Ahmad Tarhini, MD, Principal investigator, University of Pittsburgh
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00907179
- Sponsor's protocol ID
- 08-036
- Status last verified
- Jul 2015
- First submitted
- 20 May 2009
- Last updated
- 22 Jul 2015
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 22 Jul 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Pemetrexed and LBH589 in Previously-Treated Patients With Advanced Non-Small Cell Lung Cancer
- ClinicalTrials.gov ID
- NCT00907179
- Acronym / sponsor ID
- 08-036
- Conditions
- Non-Small Cell Lung Cancer
- Phase
- Phase 1
- Study type
- Interventional
- Recruitment status
- TerminatedReason stopped: Widespread use firstline Pemetrexed; slow recruitment; funding withdrawn..
- Enrolment
- 12 participants (actual)
- Lead sponsor
- University of PittsburghUniversity, hospital or other
- Collaborators
- Novartis Pharmaceuticals
- Study start
- Jul 2009
- Primary completion
- Jul 2015 (actual)
- Study completion
- Jul 2015 (actual)
- First posted
- 22 May 2009 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
LBH589 is a drug that may slow down the growth of cancer cells or kill cancer cells by blocking certain enzymes. LBH589 has shown effects against cancer in laboratory studies and in studies using animals; however, it is not known if this medicine will show the same activity in humans. As of May 2006, approximately 100 patients have received treatment with either an intravenous or capsule form of LBH589. Only the capsule form of LBH589 will be used in this study. In addition, information from other research studies and laboratory studies suggests that this study drug may help to treat lung cancer.
The main goal during the Phase I portion of this research study is to find out the highest and safest dose of LBH589 that can be given in combination with pemetrexed in subjects with lung cancer without causing severe side effects. The main goal of the Phase II portion of this study is to find how the patient's lung cancer responds to the LBH589 in combination with pemetrexed.
This study will also investigate how the patient's body processes the combination of LBH589 and pemetrexed. To determine this, the investigators will measure the amount of study drug in the patient's blood. This will be done with a series of blood tests, called pharmacokinetic (PK) tests. Other purposes of this study will be to determine the side effects of LBH589 in combination with pemetrexed and whether or not this combination is effective in treating your type of cancer.
Detailed description
Objectives
- To determine the maximum tolerated dose of LBH589 given on a three times weekly schedule when combined with pemetrexed for the treatment of patients with advanced thoracic malignancies, except squamous cell carcinoma of the lung (phase I part).
- To determine the overall response rate and non-progression rate (clinical benefit rate) and progression-free survival of the combination of LBH589 and pemetrexed in patients with previously-treated advanced NSCLC (phase II part).
- To determine the pharmacodynamic effects of LBH589 and pemetrexed on levels of histone deacetylase (HDAC) 1 and 6 in peripheral blood mononuclear cells, as well as on levels of vascular endothelial growth factor (VEGF) levels in the blood.
- To identify biomarkers in baseline, archival tumor tissue that may correlate with antitumor efficacy.
Subject population Phase I: We will enroll patients treated with any number of prior regimen and all thoracic malignancies, except squamous cell carcinoma of the lung.
Phase II: We will enroll patients with recurrent or progressive NSCLC who have received 1 prior chemotherapy regimen (1 additional regimen in the setting of initial curative treatment is allowed if completed >1 year earlier).
Treatment plan
- Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given.
- LBH589 three-times-a-week (doses will be at least 2 days apart, e.g. Monday, Wednesday, Friday), until disease progression or intolerable toxicities LBH589 will start the week prior to the first pemetrexed cycle and pharmacodynamic (PD) studies will be performed (week -1)
Study design and sample size:
This is a phase I/II study. Phase I: 9-18 patients (estimated); Phase II: 17-41 patients (estimated).
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Dose escalation | Experimental | Drug: LBH 589, Drug: PemetrexedPhase I: Determine the highest and safest dosage of LBH589 (15 mg, 20 mg, and 30 mg). If the 15 mg dosage causes too many side effects, a back-up dosage of 10 mg will be used instead of the 15 mg. Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (29 listed)
- Phase I only: any number of prior regimens is allowed and all thoracic malignancies, except squamous cell carcinoma of the lung.
- Phase II only: Patients with recurrent or progressive advanced stage non-squamous cell NSCLC (no small cell lung cancer/SCLC component) who have received 1 prior chemotherapy regimen for advanced NSCLC. Chemotherapy as part of initially potentially curative therapy that was completed <1 year counts as 1 prior regimen. Prior erlotinib or one other biologic regimen is also allowed.
- Measurable disease (RECIST) (for phase II part only)
- Patients may not have received prior pemetrexed or histone deacetylase inhibitor (HDACi) therapy, including valproic acid, for the treatment of any medical condition.
- ECOG (Eastern Cooperative Oncology Group) Performance Status of ≤ 2
Key exclusion criteria (24 listed)
- Prior HDAC, deacetylase (DAC), HSP90 inhibitors or valproic acid for the treatment of cancer
- Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first LBH589 treatment
- Impaired cardiac function including any one of the following:
- Uncontrolled hypertension. Patients with history of hypertension must be well-controlled (≤150/100) on a stable regimen of anti-hypertensive therapy.
- Concomitant use of drugs with a risk of causing torsades de pointes (See Appendix 1.-1)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LBH 589Also: PanobinstatLBH589 three-times-a-week (doses will be at least 2 days apart, e.g. Monday, Wednesday, Friday), until disease progression or intolerable toxicities LBH589 will start the week prior to the first pemetrexed cycle and PD studies will be performed (week -1). Dose level: 1 LBH589: 10 mg Pemetrexed: 500 mg/m2 Dose level: 2 LBH589: 15 mg Pemetrexed: 500 mg/m2 Dose level: 3 LBH589: 20 mg Pemetrexed: 500 mg/m2 Dose level: 4 LBH589: 30 mg Pemetrexed: 500 mg/m2 | Drug | Dose escalation |
| PemetrexedAlso: AlimtaPemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given. | Drug | Dose escalation |
Primary outcome
To determine the maximum tolerated dose of LBH589 given on a three times weekly schedule when combined with pemetrexed for the treatment of patients with advanced thoracic malignancies, except squamous cell carcinoma of the lung (phase I part)
Time frame: 6 months
3 secondary outcomes
Determine the overall response rate and non-progression rate (clinical benefit rate) and progression-free survival of the combination of LBH589 and pemetrexed in patients with previously-treated advanced NSCLC (phase II part).
Time frame: 1 year
Determine the pharmacodynamic effects of LBH589 and pemetrexed on levels of HDAC 1 and 6 in peripheral blood mononuclear cells, as well as on levels of VEGF levels in the blood.
Time frame: 1 year
Identify biomarkers in baseline, archival tumor tissue that may correlate with antitumor efficacy.
Time frame: 1 year
Results and safety
The study was stopped early (reason given: Widespread use firstline Pemetrexed; slow recruitment; funding withdrawn..). Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Jul 2015.
Related trials for Non-Small Cell Lung Cancer
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Ahmad Tarhini, MD principal investigator
University of Pittsburgh
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1 study testing LBH 589 and Pemetrexed in people with Non-Small Cell Lung Cancer, run by University of Pittsburgh at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 29 inclusion and 24 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: stopped early, as of the sponsor's last update on 22 Jul 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study was stopped early (reason given: Widespread use firstline Pemetrexed; slow recruitment; funding withdrawn..). Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
To determine the maximum tolerated dose of LBH589 given on a three times weekly schedule when combined with pemetrexed for the treatment of patients with advanced thoracic malignancies, except squamous cell carcinoma of the lung (phase I part) (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Jul 2015.